Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy
Status:
Terminated
Trial end date:
2009-08-18
Target enrollment:
Participant gender:
Summary
RATIONALE: Studying samples of blood in the laboratory from patients receiving temozolomide
may help doctors learn how temozolomide works in the body. It may also help doctors learn
more about how a patient's genes may affect the risk of developing thrombocytopenia.
PURPOSE: This clinical trial is studying the pharmacokinetics in patients with newly
diagnosed high-grade glioma receiving temozolomide and radiation therapy.
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins